NXOA.F Nicox S.A

Healthcare Biotechnology Frankfurt Exchange
0.2215 EUR
Close of Nov 13, 2026
0.2060 0.4800
Market cap
EUR 21.9M
P/E
2.8x
P/B
2.61x
ROE
-40.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NXOA.F undervalued?

Graham number
Price0.2215
Graham value0.3907
Discount43.3%

NXOA.F trades 43.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nicox S.A fundamental analysis

No fundamental analysis for Nicox S.A yet.

Nicox S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nicox S.A

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatme…

Full company profile